Overview
Balance Sheet
Cash Flow
Growth Analysis
2024
2023
2022
2021
2020
Profitability Metrics
Gross Margin
100.00%
Operating Margin
87.02%
Net Margin
86.13%
Efficiency Metrics
Revenue per Expense Ratio
7.70
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
0.00%
Income Tax Rate
0.00%
EPS
0.6400000000
Balance Sheet Analysis
Current Ratio
0.13
Cash Ratio
0.38
Working Capital
$-30.88M
Debt to Equity
0.44
Debt to Assets
30.32%
Equity Ratio
69.19%
Cash Flow Analysis
Operating Cash Flow Ratio
248.06%
Free Cash Flow Ratio
248.06%
CapEx to Revenue
0.00%
Dividends Paid
$9.50M
Stock Buybacks
$56.31M
Total Shareholder Returns
$65.81M
Cash Position Change
-98.87%
Key Takeaways (2024 FY)
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
380.29%
Net Income
334.17%
EPS
337.04%
Operating Income
336.59%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
747.16%
Operating Cash Flow
-22.97%
Free Cash Flow
-22.97%
Balance Sheet Health
Assets
-7.19%
Debt
189,565.86%
Book Value per Share
1.75%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
-11.48%
Shares Outstanding
-1.56%
Long Term Trends
3Y Revenue/Share
-20.76%
5Y Revenue/Share
-23.41%
3Y Dividend/Share
-28.54%
5Y Dividend/Share
-29.28%